New pill targets hepatitis b virus in early human trial
NCT ID NCT04536337
Summary
This early-stage study tested a new oral drug, ALG-000184, to see if it is safe and can reduce the hepatitis B virus in people with a chronic infection. The trial first gave the drug to healthy volunteers to check safety, then gave it to patients with hepatitis B, both alone and combined with a standard medication. Researchers measured virus levels in the blood to see if the treatment worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ACS
Auckland, New Zealand
-
CAP Research
Quatre Bornes, Mauritius, 72218, Mauritius
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova
-
Prince of Wales
Shatin, Hong Kong
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Saint Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
-
Western Health
Footscray, Victoria, 3011, Australia
Conditions
Explore the condition pages connected to this study.